Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donor hematopoietic cell transplantation + total lymphoid irradiation + anti-thymocyte globulin
- Development stage
- Unknown
- Lead developer
- Stanford University
- Modality
- Antibody-Based Therapeutics, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This therapeutic regimen, developed at Stanford University, is an investigational protocol designed to induce immune tolerance in adult HLA-matched living donor kidney transplant recipients. The procedure utilizes a non-myeloablative conditioning phase consisting of total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG), followed by the infusion of donor-derived hematopoietic stem cells (CD34+ cells) and T cells (CD3+ cells). By establishing a state of transient or persistent mixed chimerism, the regimen aims to "re-educate" the recipient's immune system to recognize the donor organ as self. The primary clinical objective is to facilitate the complete and safe withdrawal of maintenance immunosuppressive drugs, thereby avoiding long-term medication toxicities while preventing graft rejection.
- Other names
- Stanford ProtocolStanford TLI-ATG RegimenImmune Tolerance in HLA-Matched Living Donor Kidney Transplantation Regimen
Beyond the preview
Go deeper on donor hematopoietic cell transplantation + total lymphoid irradiation + anti-thymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donor hematopoietic cell transplantation + total lymphoid irradiation + anti-thymocyte globulin.